Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer

CompletedOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2012

Conditions
Metastatic Breast Cancer
Trial Locations (17)

Unknown

Hospital Comarcal de Barbastro, Huesca

Complejo Hospitalario de Jaen, Jaén

Hospital Arnau de Vilanova, Lleida

Clínica Román, Madrid

Hospital 12 de Octubre, Madrid

Hospital Clínico San Carlos, Madrid

Hospital Madrid Norte Sanchinarro, Madrid

Hospital MD Anderson, Madrid

Hospital Quirón Madrid, Madrid

Hospital Sanitas La Moraleja, Madrid

Hospital Universitario Morales Meseguer, Murcia

Hospital de Navarra, Navarra

Hospital Clínico Universitario de Salamanca, Salamanca

Clínica Esperanza de Triana, Seville

Hospital Universitario Virgen del Rocío, Seville

Hospital Virgen Macarena, Seville

Hospital Miguel Servet, Zaragoza

All Listed Sponsors
lead

Eisai Farmacêutica S.A.

INDUSTRY

NCT02790320 - Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer | Biotech Hunter | Biotech Hunter